Compounds which are PPAR delta agonists are described. These compounds are useful for raising high density lipoprotein (HDL) plasma levels in mammals and for preventing, halting or slowing the progression of atherosclerotic cardiovascular diseases and related conditions and disease events. PPAR delta agonists can be administered alone or in combination with additional active agents such as LDL-lowering agents.
